Intercept Pharmaceut (ICPT) 169.72 $ICPT
BioMarin (BMRN) May Beat in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:04AM CDT
BioMarin (BMRN), which is scheduled to report second-quarter 2016 results on Aug 4, had delivered a positive earnings surprise of 58.82% last quarter.
BMRN: 100.25 (+0.83), CNAT: 2.29 (+0.03), ICPT: 169.72 (-3.31), EXEL: 9.27 (+0.09)
Zoetis (ZTS): Stock to Beat Earnings Estimates in Q2 Again
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:01AM CDT
Zoetis (ZTS), which is set to report second-quarter 2016 results on Aug 3, had delivered a positive earnings surprise of 17.07% last quarter.
ZTS: 50.40 (-0.07), ABT: 45.29 (+0.54), ICPT: 169.72 (-3.31), EXEL: 9.27 (+0.09)
Pfizer (PFE) Likely to Beat Earnings in Q2 Again
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 2:51PM CDT
Pfizer (PFE), which is set to report second-quarter 2016 results on Aug 2, had delivered a positive earnings surprise of 21.82% last quarter. Will it beat estimates again?
BMRN: 100.25 (+0.83), PFE: 37.31 (+0.42), ICPT: 169.72 (-3.31), EXEL: 9.27 (+0.09)
Intercept to Report Second Quarter 2016 Financial Results on August 4 and Present at Upcoming Conference
GlobeNewswire - Thu Jul 28, 6:06AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report its second quarter 2016 financial results prior to the NASDAQ market open on Thursday, August 4, 2016. Intercept management will conduct a conference call and audio webcast on Thursday, August 4, 2016 at 8:30 a.m. Eastern Time to discuss these results.
ICPT: 169.72 (-3.31)
AbbVie (ABBV) Q2 Earnings: Will the Stock Pull a Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 9:11AM CDT
Will Imbruvica and Humira help AbbVie (ABBV) deliver a positive earnings surprise in Q2?
JNJ: 125.40 (+0.17), ICPT: 169.72 (-3.31), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), BMY: 76.19 (+1.38)
Merck (MRK) Q2 Earnings: Will the Stock Pull a Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 6:24AM CDT
Merck (MRK) had posted a positive earnings surprise in Q1. Will the stock deliver a positive surprise again this quarter?
BMRN: 100.25 (+0.83), MRK: 58.66 (unch), ICPT: 169.72 (-3.31), AMGN: 174.16 (+2.13)
Vertex (VRTX) to Report Q2 Earnings: Is a Surprise in Store?
Arpita Dutt - Zacks Investment Research - Mon Jul 25, 6:54AM CDT
Will Orkambi and Kalydeco help Vertex (VRTX) surpass expectations in Q2?
VRTX: 98.20 (+1.20), BMRN: 100.25 (+0.83), ICPT: 169.72 (-3.31), AMGN: 174.16 (+2.13)
Amgen (AMGN) May Beat Q2 Earnings: Will the Stock Gain?
Arpita Dutt - Zacks Investment Research - Mon Jul 25, 6:36AM CDT
Our proven model shows that Amgen (AMGN) is likely to beat earnings because it has the right combination of two key ingredients.
BMRN: 100.25 (+0.83), ICPT: 169.72 (-3.31), AMGN: 174.16 (+2.13), FMS: 45.65 (unch)
Intercept Pharmaceuticals Announces Closing of Public Offering of Convertible Senior Notes and Exercise in Full of Option to Purchase Additional Notes
GlobeNewswire - Wed Jul 06, 4:05PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) announced today the closing of its previously announced underwritten public offering of $460 million aggregate principal amount of 3.25% convertible senior notes due 2023 (the notes), including the full exercise by the underwriters of an option to purchase an additional $60 million in aggregate principal amount of notes to cover over-allotments. As a result, Intercept anticipates that the aggregate net proceeds, after deducting the underwriting discount and estimated offering expenses payable by Intercept, will be approximately $447.7 million.
ICPT: 169.72 (-3.31)
Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement of Intercept Pharmaceuticals, Inc. Securities Litigation
PR Newswire - Mon Jun 20, 10:30AM CDT
The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Intercept Pharmaceuticals, Inc. Securities Litigation:
ICPT: 169.72 (-3.31)
Intercept Pharmaceuticals Appoints Sandip Kapadia as Chief Financial Officer
GlobeNewswire - Thu Jun 09, 4:35PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced the appointment of Sandip Kapadia as Chief Financial Officer. Mr. Kapadia will succeed Barbara Duncan effective July 1, who has served as CFO for Intercept since 2009. Ms. Duncan and Mr. Kapadia will work closely through a transition period to support a seamless change in leadership.
ICPT: 169.72 (-3.31)
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
BIIB: 301.83 (+11.90), SRPT: 25.91 (+0.63), ICPT: 169.72 (-3.31), ABBV: 66.94 (+0.71), IONS: 38.01 (+8.82)
Intercept to Present at Upcoming Investor Conferences
GlobeNewswire - Wed Jun 01, 3:05PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced management will be participating in the following investor conferences:
ICPT: 169.72 (-3.31)
Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Jun 01, 1:40PM CDT
With the annual meeting of ASCO coming up, watch out for updates from several biotech companies on their cancer treatments.
BIIB: 301.83 (+11.90), VRTX: 98.20 (+1.20), GILD: 80.46 (+0.99), SRPT: 25.91 (+0.63), ICPT: 169.72 (-3.31), ABBV: 66.94 (+0.71), IONS: 38.01 (+8.82)
Intercept's (ICPT) Liver Dug Ocaliva Approved by the FDA
Zacks Equity Research - Zacks Investment Research - Mon May 30, 7:46AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) announced that the FDA has granted accelerated approval to Ocaliva (obeticholic acid), in combination with ursodeoxycholic (UDCA).
ANIP: 61.06 (+0.46), PFE: 37.31 (+0.42), ICPT: 169.72 (-3.31), BMY: 76.19 (+1.38)
FDA Grants Accelerated Approval to Ocaliva(TM) (Obeticholic Acid) for the Treatment of Patients with PBC
GlobeNewswire - Fri May 27, 10:42PM CDT
First new medicine for PBC in nearly 20 years
ICPT: 169.72 (-3.31)
Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well
Arpita Dutt - Zacks Investment Research - Wed May 25, 2:02PM CDT
Deals and acquisitions were in focus this week in the biotech sector while AbbVie's (ABBV) recently in-licensed candidate fared well in a mid-stage study.
VRTX: 98.20 (+1.20), HZNP: 18.89 (-0.40), ICPT: 169.72 (-3.31), ABBV: 66.94 (+0.71), ACOR: 25.13 (-0.15), BIOD: 0.41 (-0.03), XNPT: 7.07 (+0.05)
Why These Biotech Stocks Have Been on Investors' Radar? - Juno Therapeutics, Immunomedics, Ultragenyx Pharma, and Intercept Pharma
PR Newswire - Wed May 25, 7:10AM CDT
The Biotech arena may not be in its best shape right now, but this does not mean investors are sidelining stocks in this space. Here are today's ActiveWallSt.com highlights: Juno Therapeutics Inc. (NASDAQ: JUNO), Immunomedics Inc. (NASDAQ: IMMU), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Get the free access these stocks' technical alerts by clicking below:
IMMU: 2.80 (+0.15), RARE: 63.53 (+0.25), ICPT: 169.72 (-3.31), JUNO: 30.86 (-0.07)
Adaptimmune Strengthens Board with Appointment of Barbara Duncan
GlobeNewswire - Tue May 24, 6:30AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP) ("Adaptimmune" or the "Company"
, a leader in T-cell therapy to treat cancer, today announced the appointment of Barbara Duncan to its Board of Directors as an independent Non-Executive Director effective from June 23, 2016. Ms. Duncan will also serve as a member of the Audit Committee.
MDGN: 6.03 (+0.26), ICPT: 169.72 (-3.31), ADAP: 8.35 (+0.23)
Intercept Announces Ocaliva(TM) (Obeticholic Acid) Data in PBC to be Presented at DDW 2016
GlobeNewswire - Wed May 18, 10:00AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, announced today that five abstracts evaluating obeticholic acid (OCA) in patients with primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH) will be presented at Digestive Disease Week (DDW) in San Diego, California from May 21-24, 2016. OCA is an investigational product and has not been granted marketing authorization or approval from any regulatory authority.
ICPT: 169.72 (-3.31)
BioMarin (BMRN) May Beat in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:04AM CDT
BioMarin (BMRN), which is scheduled to report second-quarter 2016 results on Aug 4, had delivered a positive earnings surprise of 58.82% last quarter.
BMRN: 100.25 (+0.83), CNAT: 2.29 (+0.03), ICPT: 169.72 (-3.31), EXEL: 9.27 (+0.09)
Zoetis (ZTS): Stock to Beat Earnings Estimates in Q2 Again
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:01AM CDT
Zoetis (ZTS), which is set to report second-quarter 2016 results on Aug 3, had delivered a positive earnings surprise of 17.07% last quarter.
ZTS: 50.40 (-0.07), ABT: 45.29 (+0.54), ICPT: 169.72 (-3.31), EXEL: 9.27 (+0.09)
Pfizer (PFE) Likely to Beat Earnings in Q2 Again
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 2:51PM CDT
Pfizer (PFE), which is set to report second-quarter 2016 results on Aug 2, had delivered a positive earnings surprise of 21.82% last quarter. Will it beat estimates again?
BMRN: 100.25 (+0.83), PFE: 37.31 (+0.42), ICPT: 169.72 (-3.31), EXEL: 9.27 (+0.09)
Intercept to Report Second Quarter 2016 Financial Results on August 4 and Present at Upcoming Conference
GlobeNewswire - Thu Jul 28, 6:06AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report its second quarter 2016 financial results prior to the NASDAQ market open on Thursday, August 4, 2016. Intercept management will conduct a conference call and audio webcast on Thursday, August 4, 2016 at 8:30 a.m. Eastern Time to discuss these results.
ICPT: 169.72 (-3.31)
AbbVie (ABBV) Q2 Earnings: Will the Stock Pull a Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 9:11AM CDT
Will Imbruvica and Humira help AbbVie (ABBV) deliver a positive earnings surprise in Q2?
JNJ: 125.40 (+0.17), ICPT: 169.72 (-3.31), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), BMY: 76.19 (+1.38)
Merck (MRK) Q2 Earnings: Will the Stock Pull a Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 6:24AM CDT
Merck (MRK) had posted a positive earnings surprise in Q1. Will the stock deliver a positive surprise again this quarter?
BMRN: 100.25 (+0.83), MRK: 58.66 (unch), ICPT: 169.72 (-3.31), AMGN: 174.16 (+2.13)
Vertex (VRTX) to Report Q2 Earnings: Is a Surprise in Store?
Arpita Dutt - Zacks Investment Research - Mon Jul 25, 6:54AM CDT
Will Orkambi and Kalydeco help Vertex (VRTX) surpass expectations in Q2?
VRTX: 98.20 (+1.20), BMRN: 100.25 (+0.83), ICPT: 169.72 (-3.31), AMGN: 174.16 (+2.13)
Amgen (AMGN) May Beat Q2 Earnings: Will the Stock Gain?
Arpita Dutt - Zacks Investment Research - Mon Jul 25, 6:36AM CDT
Our proven model shows that Amgen (AMGN) is likely to beat earnings because it has the right combination of two key ingredients.
BMRN: 100.25 (+0.83), ICPT: 169.72 (-3.31), AMGN: 174.16 (+2.13), FMS: 45.65 (unch)
Intercept Pharmaceuticals Announces Closing of Public Offering of Convertible Senior Notes and Exercise in Full of Option to Purchase Additional Notes
GlobeNewswire - Wed Jul 06, 4:05PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) announced today the closing of its previously announced underwritten public offering of $460 million aggregate principal amount of 3.25% convertible senior notes due 2023 (the notes), including the full exercise by the underwriters of an option to purchase an additional $60 million in aggregate principal amount of notes to cover over-allotments. As a result, Intercept anticipates that the aggregate net proceeds, after deducting the underwriting discount and estimated offering expenses payable by Intercept, will be approximately $447.7 million.
ICPT: 169.72 (-3.31)
Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement of Intercept Pharmaceuticals, Inc. Securities Litigation
PR Newswire - Mon Jun 20, 10:30AM CDT
The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Intercept Pharmaceuticals, Inc. Securities Litigation:
ICPT: 169.72 (-3.31)
Intercept Pharmaceuticals Appoints Sandip Kapadia as Chief Financial Officer
GlobeNewswire - Thu Jun 09, 4:35PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced the appointment of Sandip Kapadia as Chief Financial Officer. Mr. Kapadia will succeed Barbara Duncan effective July 1, who has served as CFO for Intercept since 2009. Ms. Duncan and Mr. Kapadia will work closely through a transition period to support a seamless change in leadership.
ICPT: 169.72 (-3.31)
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
BIIB: 301.83 (+11.90), SRPT: 25.91 (+0.63), ICPT: 169.72 (-3.31), ABBV: 66.94 (+0.71), IONS: 38.01 (+8.82)
Intercept to Present at Upcoming Investor Conferences
GlobeNewswire - Wed Jun 01, 3:05PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced management will be participating in the following investor conferences:
ICPT: 169.72 (-3.31)
Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Jun 01, 1:40PM CDT
With the annual meeting of ASCO coming up, watch out for updates from several biotech companies on their cancer treatments.
BIIB: 301.83 (+11.90), VRTX: 98.20 (+1.20), GILD: 80.46 (+0.99), SRPT: 25.91 (+0.63), ICPT: 169.72 (-3.31), ABBV: 66.94 (+0.71), IONS: 38.01 (+8.82)
Intercept's (ICPT) Liver Dug Ocaliva Approved by the FDA
Zacks Equity Research - Zacks Investment Research - Mon May 30, 7:46AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) announced that the FDA has granted accelerated approval to Ocaliva (obeticholic acid), in combination with ursodeoxycholic (UDCA).
ANIP: 61.06 (+0.46), PFE: 37.31 (+0.42), ICPT: 169.72 (-3.31), BMY: 76.19 (+1.38)
FDA Grants Accelerated Approval to Ocaliva(TM) (Obeticholic Acid) for the Treatment of Patients with PBC
GlobeNewswire - Fri May 27, 10:42PM CDT
First new medicine for PBC in nearly 20 years
ICPT: 169.72 (-3.31)
Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well
Arpita Dutt - Zacks Investment Research - Wed May 25, 2:02PM CDT
Deals and acquisitions were in focus this week in the biotech sector while AbbVie's (ABBV) recently in-licensed candidate fared well in a mid-stage study.
VRTX: 98.20 (+1.20), HZNP: 18.89 (-0.40), ICPT: 169.72 (-3.31), ABBV: 66.94 (+0.71), ACOR: 25.13 (-0.15), BIOD: 0.41 (-0.03), XNPT: 7.07 (+0.05)
Why These Biotech Stocks Have Been on Investors' Radar? - Juno Therapeutics, Immunomedics, Ultragenyx Pharma, and Intercept Pharma
PR Newswire - Wed May 25, 7:10AM CDT
The Biotech arena may not be in its best shape right now, but this does not mean investors are sidelining stocks in this space. Here are today's ActiveWallSt.com highlights: Juno Therapeutics Inc. (NASDAQ: JUNO), Immunomedics Inc. (NASDAQ: IMMU), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Get the free access these stocks' technical alerts by clicking below:
IMMU: 2.80 (+0.15), RARE: 63.53 (+0.25), ICPT: 169.72 (-3.31), JUNO: 30.86 (-0.07)
Adaptimmune Strengthens Board with Appointment of Barbara Duncan
GlobeNewswire - Tue May 24, 6:30AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP) ("Adaptimmune" or the "Company"
, a leader in T-cell therapy to treat cancer, today announced the appointment of Barbara Duncan to its Board of Directors as an independent Non-Executive Director effective from June 23, 2016. Ms. Duncan will also serve as a member of the Audit Committee. MDGN: 6.03 (+0.26), ICPT: 169.72 (-3.31), ADAP: 8.35 (+0.23)
Intercept Announces Ocaliva(TM) (Obeticholic Acid) Data in PBC to be Presented at DDW 2016
GlobeNewswire - Wed May 18, 10:00AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, announced today that five abstracts evaluating obeticholic acid (OCA) in patients with primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH) will be presented at Digestive Disease Week (DDW) in San Diego, California from May 21-24, 2016. OCA is an investigational product and has not been granted marketing authorization or approval from any regulatory authority.
ICPT: 169.72 (-3.31)
